Pharmaceuticals News and Research

RSS

PAREXEL International launches temperature recording solution optimized for clinical trial supply process

PAREXEL International Corporation, a leading global biopharmaceutical services organization, today announced that it has introduced an integrated temperature recording solution for study drug transportation as part of its expanded Clinical Logistics Services.

From Parexel 19 Aug 2010

PharmaVentures announces global expansion of PharmaDeals Agreements

PharmaVentures, the company behind the PharmaDeals(R) range of business information, announced today the expansion of its PharmaDeals Agreements coverage that includes exclusive interviews with deal makers around the world. The announcement follows major enhancement of its dedicated, market leading platform delivering deal data and information to the pharmaceutical and biotechnology sector.

19 Aug 2010

Montana Pain Management in breach of non-disclosure/non-circumvention agreement with Cannabis Science

Cannabis Science Inc., a pioneering US biotech company developing pharmaceutical cannabis products, reports that Cannabis Science sent an email to Mr. Rick Rosio on July 23, 2010 notifying him that he appeared to be in serious breach of the non-disclosure/non-circumvention agreement that he and Montana Pain Management, Inc., had signed with Cannabis Science.

19 Aug 2010

Elephant Capital and ClinTec International announce partnership deal

ClinTec International, a global Clinical Research Organisation ("CRO") announces financial and strategic partnership with Elephant Capital plc., a London AIM market listed private equity firm. With an investment of £8 Million GBP, Elephant has acquired a significant minority stake in ClinTec.

19 Aug 2010

Dr. Hartung receives Agilent Thought Leader Award for developmental neurotoxicity research

Agilent Technologies Inc. and the Agilent Foundation today announced that Dr. Thomas Hartung has received an Agilent Thought Leader Award in support of his research for the use of toxicity pathways to predict developmental neurotoxicity. This work could help identify possible contributions of chemicals to disorders such as autism and attention hyperactivity disorders.

19 Aug 2010

USFDA approves Sun Pharma's generic Venlafaxine Hydrochloride Extended Release tablets ANDA

Sun Pharma announced that USFDA has granted an approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Venlafaxine Hydrochloride Extended Release tablets.

19 Aug 2010

EHSI signs option with Regenevita for 'Neo Natal Progenitor Cell Expansion Technology'

Emerging Healthcare Solutions, Inc. announced today that the Company has signed an option with Regenevita, owner of the right to license Neo Natal Progenitor Cell Expansion Technology in Latin America. The core technology on which the Regenevita technology is based was originally developed by NASA, the National Aeronautics and Space Administration, and was sub-licensed to Regenevita for use with Neo Natal Progenitor Cell Expansion.

19 Aug 2010

Cannabis Science signs manufacturing and development license with RockBrook

Cannabis Science Inc. a pioneering US biotech company developing pharmaceutical cannabis products, announces that on August 18, 2010, Cannabis Science signed with RockBrook Inc., its first manufacturing and development license for the Cannabis Science Brand of Pharmaceutical Products for the State of Colorado.

19 Aug 2010

Achillion Pharmaceuticals enters agreement to raise $50.1 million from sale of common stock

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that it has entered into definitive agreements for the purchase of $50.1 million of Achillion's common stock and warrants in a private placement financing with a select group of institutional and accredited investors, namely Domain Associates, Clarus Ventures, Quaker BioVentures and Pappas Ventures.

19 Aug 2010

China PharmaHub and Chengdu Yongkon Pharmacy sign cooperation agreement

China PharmaHub Corp., recently merged with World Wide Relics, which will be shortly changing its name to China PharmaHub Corp, is proud to announce it has signed a cooperation agreement with Chengdu Yongkon Pharmacy Co. Ltd., a pharmaceutical company based in Sichuan, with an established sales network of over 2600 hospitals in China.

18 Aug 2010

Intellect Neurosciences locks database of OXIGON Phase 1b clinical trial for Alzheimer's disease

Intellect Neurosciences, Inc. a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has locked the database of the Company's Phase 1b clinical trial for its lead Alzheimer's candidate, OXIGON™ (OX1).

18 Aug 2010

USPTO grants Collegium second patent for tamper-resistant DETERx formulation platform

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that a new patent has been issued by the U.S. Patent and Trademark Office (USPTO) relating to its tamper-resistant DETERx™ formulation platform. US Patent Number 7,771,707 contains claims that cover Collegium's proprietary extended-release formulations, which are designed to resist dose dumping when subjected to a variety of physical methods of tampering.

18 Aug 2010

Wound Management Technologies' CellerateRX introduced at DFWG congress in South Africa

Wound Management Technologies, Inc. announced today that its new international distributor, Spiramed (Pty) Ltd, exhibited its advanced wound care collagen product, CellerateRX® last weekend at the DFWG (Diabetic Foot Working Group) congress in Cape Town and has already planned exhibitions at two additional upcoming conferences. This second meeting of the DFWG congress was attended by over 120 diabetic foot specialists.

18 Aug 2010

Biogen Idec, Knopp Neurosciences enter license agreement for KNS-760704 ALS drug candidate

Biogen Idec and Knopp Neurosciences today announced they have entered into an exclusive, worldwide license agreement under which Biogen Idec will develop and commercialize KNS-760704 (dexpramipexole) for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, and potentially other indications.

18 Aug 2010

Experts to discuss the problem of antibiotic resistance

The growing problem of antibiotic resistance, which compromises our ability to treat common infections, represents one of the greatest threats to public health worldwide. Researchers, politicians and representatives from public health organisations and the pharmaceutical industry will gather in Uppsala from 6-8 September to discuss global strategies.

18 Aug 2010

Regenicin acquires worldwide exclusive license to know-how technology

Regenicin, Inc., a development stage biotechnology company, announced today that it has completed an initial $3.25 million funding in conjunction with its acquisition of a worldwide exclusive license to know-how technology controlled by Lonza Walkersville ("Lonza Agreement").

18 Aug 2010

PBM Medco invests in comparative-effectiveness, safety research firm

The Wall Street Journal reports that pharmacy benefit manager Medco Health Solutions will buy United BioSource, a business that conducts safety and comparative effectiveness research, for $730 million.

18 Aug 2010

Quark enters licensing option agreement with Novartis for p53 temporary inhibitor siRNA drug QPI-1002

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.

18 Aug 2010

Study finds pharmaceuticals as a two-tier market for producing 'lemons' and serious harm

The pharmaceutical industry is a "market for lemons," a market in which the seller knows much more than the buyer about the product and can profit from selling products less effective and less safe than consumers are led to believe, according to an analysis that will be presented at the 105th Annual Meeting of the American Sociological Association.

18 Aug 2010

Endocyte files registration statement for public offering of common stock

Endocyte, Inc., a biopharmaceutical company developing targeted small-molecule drug conjugates, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock.

18 Aug 2010

Pharmaceuticals News and Research

PAREXEL International launches temperature recording solution optimized for clinical trial supply process

PharmaVentures announces global expansion of PharmaDeals Agreements

Montana Pain Management in breach of non-disclosure/non-circumvention agreement with Cannabis Science

Elephant Capital and ClinTec International announce partnership deal

Dr. Hartung receives Agilent Thought Leader Award for developmental neurotoxicity research

USFDA approves Sun Pharma's generic Venlafaxine Hydrochloride Extended Release tablets ANDA

EHSI signs option with Regenevita for 'Neo Natal Progenitor Cell Expansion Technology'

Cannabis Science signs manufacturing and development license with RockBrook

Achillion Pharmaceuticals enters agreement to raise $50.1 million from sale of common stock

China PharmaHub and Chengdu Yongkon Pharmacy sign cooperation agreement

Intellect Neurosciences locks database of OXIGON Phase 1b clinical trial for Alzheimer's disease

USPTO grants Collegium second patent for tamper-resistant DETERx formulation platform

Wound Management Technologies' CellerateRX introduced at DFWG congress in South Africa

Biogen Idec, Knopp Neurosciences enter license agreement for KNS-760704 ALS drug candidate

Experts to discuss the problem of antibiotic resistance

Regenicin acquires worldwide exclusive license to know-how technology

PBM Medco invests in comparative-effectiveness, safety research firm

Quark enters licensing option agreement with Novartis for p53 temporary inhibitor siRNA drug QPI-1002

Study finds pharmaceuticals as a two-tier market for producing 'lemons' and serious harm

Endocyte files registration statement for public offering of common stock

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence